The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 19, 1999

Filed:

Dec. 23, 1997
Applicant:
Inventors:

Karol K LaCroix, Holly Springs, NC (US);

Christy L Shaffer, Chapel Hill, NC (US);

Karla M Jacobus, Carey, NC (US);

Janet L Rideout, Raleigh, NC (US);

David J Drutz, Chapel Hill, NC (US);

Richard C Evans, Carey, NC (US);

William Pendergast, Durham, NC (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ;
U.S. Cl.
CPC ...
514 47 ; 424 45 ; 424 47 ;
Abstract

Novel pharmaceutical compositions of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears or sinuses are disclosed. Novel Formulation I comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg/mL, a controlled tonicity within the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted composition is capable of long-term storage in the refrigerated state with a shelf life of up to 30 months. Formulation I may be delivered therapeutically either in a nebulized form or in a liquid form. Novel Formulation II comprises UTP in an aqueous solution or suspension having a therapeutic concentration approaching the limit of UTP's solubility at ambient temperature. This high concentration allows delivery of a therapeutic amount of UTP in very small volumes (50 to 100 .mu.L) suitable for administration via portable hand-held devices such as metered dose inhalers. Formulation II has extended shelf life without the need for refrigeration after being dispensed to the patient.


Find Patent Forward Citations

Loading…